Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.89 USD | -5.50% | -4.55% | +21.94% |
Financials (USD)
Sales 2024 * | 108M | Sales 2025 * | 75.98M | Capitalization | 147M |
---|---|---|---|---|---|
Net income 2024 * | -17M | Net income 2025 * | -50M | EV / Sales 2024 * | 1.36 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 1.94 x |
P/E ratio 2024 * |
-9.36
x | P/E ratio 2025 * |
-3.95
x | Employees | 121 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.97% |
Latest transcript on CytomX Therapeutics, Inc.
1 day | -5.50% | ||
1 week | -4.55% | ||
Current month | +15.95% | ||
1 month | +9.25% | ||
3 months | +28.57% | ||
6 months | +43.18% | ||
Current year | +21.94% |
Managers | Title | Age | Since |
---|---|---|---|
Sean McCarthy
CEO | Chief Executive Officer | 57 | 10-11-30 |
Chris Ogden
DFI | Director of Finance/CFO | 40 | 21-08-01 |
Marcia Belvin
CTO | Chief Tech/Sci/R&D Officer | 57 | 17-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
James Meyers
BRD | Director/Board Member | 59 | 18-12-19 |
Elaine Jones
BRD | Director/Board Member | 69 | 14-11-30 |
Sean McCarthy
CEO | Chief Executive Officer | 57 | 10-11-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-17 | 1.89 | -5.50% | 3,538,621 |
24-05-16 | 2 | +2.04% | 3,288,698 |
24-05-15 | 1.96 | +1.03% | 3,922,236 |
24-05-14 | 1.94 | +2.65% | 4,577,284 |
24-05-13 | 1.89 | -4.55% | 6,114,521 |
Delayed Quote Nasdaq, May 17, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+21.94% | 147M | |
+9.42% | 115B | |
+11.84% | 106B | |
-1.05% | 21.96B | |
-14.15% | 21.87B | |
-5.29% | 19.21B | |
-4.16% | 18.08B | |
-38.29% | 17.71B | |
+7.99% | 14.32B | |
+36.24% | 12.42B |
- Stock Market
- Equities
- CTMX Stock